This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Lawsuit by former longtime sales representative claims Exact Sciences Corp. made false promises in order to hire him, then forced him to resign, which he did.
Pfizer's success in developing COVID medicines has given the drugmaker unusual weight in determining U.S. health policy.
When Albert Bourla said all Americans will need a second booster shot, some experts saw his claim as self-serving.
The rollout would begin the week of Sept. 20 for U.S. residents 18 and older who received their second shot of the Moderna or Pfizer-BioNTech vaccines at least eight months previously.
As pharmaceutical companies declare a need for boosters, scientists and doctors emphasize that there’s no proof yet.
A Pfizer win in a lawsuit against the federal government could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts.
Booster shots are likely to be here before long because of the outdated, 60-year-old basic standard the Food and Drug Administration uses to authorize medicines for sale.
The Centers for Disease Control and Prevention is set to meet on Friday to discuss whether rare instances of a heart disorder merit changing its recommendations for vaccinating teenagers with the Pfizer vaccine.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state has enough supplies of Pfizer, Moderna and Johnson & Johnson doses to last about 80 days at current vaccination pace.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
A drop in demand increases pressure on public health officials to come up with new strategies to get people vaccinated.
